Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...
GLP-1 drugs do a lot more than just help you lose weight. They can help your heart, brain, and more, but beware what they ...
Even so, this relatively lean state had among the nation’s biggest surges last year in residents taking blockbuster weight-loss drugs ... such as Wegovy and Zepbound in 2024, a 255 percent ...
Weight loss was still increasing at Week 36, implying Kailera and Hengrui Pharma can go past 22.8%. The data suggest HRS9531 has similar efficacy to Eli Lilly’s Zepbound. Lilly won approval for ...
Hosted on MSN9h
Ozempic and similar weight loss drugs may lower risk of 42 health conditions, but also pose risksThe Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...
The proportion of obese Indians has risen from 25 per cent in 2013 to 40 per cent in 2023, highlighting the need for ...
and more than 92% were men, so the study results may not apply to other types of GLP-1 users. And everyone in the study had diabetes, so no one was taking these medications solely for weight loss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback